Disclaimer

This presentation contains forward-looking statements including statements that address activities, events or developments that BioSig expects, believes or anticipates will or may occur in the future, such as predictions of financial performance, approvals and launches by BioSig of new products, market acceptance of BioSig’s products, market and procedure projections, financing plans, and related documents. Forward-looking statements are based on BioSig’s experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond BioSig’s control.

These risks and uncertainties include the timing of approvals for BioSig products, rate and degree of market acceptance of products, BioSig’s ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products and the impact of failure to obtain such clearances and approvals on its ability to promote its products and train doctors and operators in the use of its products, the timing of and ability to obtain reimbursement if required of procedures utilizing BioSig’s products and the potential impact of current healthcare reform initiatives thereon, competition from existing and new products and procedures or BioSig’s ability to effectively react to other risks and uncertainties described from time to time in BioSig’s SEC filings, such as fluctuation of financial results, reliance on third party manufacturers and suppliers, litigation or other proceedings, government regulation, negative publicity, current worldwide economic conditions and share price volatility.

BioSig does not guarantee any forward-looking statements, and actual results may differ materially from those projected. Unless required by law, BioSig undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Who We Are – NASDAQ: BSGM

- Secular double-digit growth market
  - Fastest growth in cardiology
- Global EP Market Expected to be $12.2 billion by 2026*
- Solves clear unmet need in the operating room
- 31 patents issued
  - no direct competition
- Razor & Blade business model
- FDA approved

Data source: MarketWatch Global Electrophysiology Device Market Could Exceed $12.2 Billion by 2026
Global EP Procedures Growing Rapidly
Cardiac Ablation Procedures Are Key Hospital Revenue Drivers

Complex Cardiac Ablation:
13.5% growth rate

U.S.:
3,425 EP labs

OUS:
3,915 EP labs

Data source: 2018 MD&D report Advisory Board
Published by Cardiovascular Rounds, Guggenheim Analyst - Chris Pasquale
PURE EP™ System
• Catheters inside the heart collect analog signals

• Signals are sent to a junction box

• BioSig’s PURE EP™ system pulls signals from junction box

• Digitizes raw signals

• Displays information for physician
Challenges in EP For All Stakeholders

**Physicians Can’t Fix What They Can’t See**

**Signal Quality**
81% of physicians rated signal quality as “Critical”

**Success Rate**
45% of ablations are unsuccessful

Data source: PUBMED 11/2017
“The PURE EP System does provide innovative design with greater resolution and greater bandwidth, which should allow for safer and more efficacious ablations in the future.”

- K. Venkatachalam, M.D., Cardiac Electrophysiologist, Mayo Clinic

“The quality of the recording that we can get in the lab can make a big difference [during the procedure]. . . The PURE EP System clearly gave us better quality of intracardiac recording [compared to conventional systems.]”

- Andrea Natale, M.D., Texas Cardiac Arrhythmia Institute
Florida
120 EP Programs
240 Labs

Texas
220 EP Programs
440 Labs

Commercialization – Regions and Centers of Excellence
Veterans from Industry Drive the Business

Kenneth L. Londoner, MBA
Founder, Chairman, CEO, Director
NeuroClear Technologies; Endicott Management Partners; J & W Seligman & Co.

Natasha Drapeau
Executive Vice President
NeuroClear Technologies; Alliance for Advancing Bioelectronic Medicine; Institute of Directors, UK; IG Group Plc, UK

Todd Wiltshire
Senior Vice President, Corporate Development
Fidelity Investments; Credit Agricole; UBS; Morgan Stanley

John Kowalski
Vice President, Sales
Biosense Webster (Johnson & Johnson)

Manasi Patwardhan
Director of Strategic Planning
Verily Life Sciences, Boston Scientific - Neuromodulation; Medtronic

Steve Chaussy, CPA
CFO
NeuroClear Technologies; Liberski Inc; Anna & Co; Penske Automotive; Ford Hogg and Cobbe

Andy Ballou
Vice President, Investor Relations
Janney Montgomery Scott; RBC Capital Markets

Barry Keenan, Ph.D, MBA, PMP
Vice President, Engineering
Medtronic; Nexeon MedSystems; Alfred Mann Institute for Biomedical Engineering; Alfred Mann Foundation for Scientific Research

Julie Stephenson, BSN, MBA
Vice President, Clinical Affairs
Medtronic; Boston Scientific; Guidant Corporation

Olivier Chaudoir
Senior Director, Marketing
Biosense Webster; DePuy Synthes
Value Drivers

- Raised $41 million in 2020.
- $32 million in cash on the balance sheet and no debt.
- First commercial revenues Q4 2020.
- Expect to triple the customer base in 2021.
- CE mark approval / EU entry Q4 2021
- Sequential revenue growth in 2021

Nasdaq: BSGM